28,411
Participants
Start Date
December 7, 2021
Primary Completion Date
December 30, 2022
Study Completion Date
December 30, 2022
self-administered lateral flow assays
The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
NHS Blood and Transplant, Bristol
Imperial College, London
Ipsos Mori, London
National Disease Registration Service, London
NHS Blood and Transplant
OTHER_GOV
IPSOS
INDUSTRY
University of Nottingham
OTHER
Nottingham University Hospitals NHS Trust
OTHER
Imperial College London
OTHER